title: Combination oral antiplatelet therapy may increase the risk of hemorrhagic complications in patients with acute ischemic stroke caused by large artery disease.
abstract: BACKGROUND
  The association between the frequency or severity of bleeding complications and combination antiplatelet therapy for acute stroke treatment is not understood in detail. This retrospective study investigated whether combination oral antiplatelet therapy for cases with acute ischemic stroke due to large artery disease increased the incidence of hemorrhagic complications.
  
  
  METHODS
  We reviewed 1335 consecutive patients who were admitted to our department within 7 days of the onset of an ischemic stroke or transient ischemic attack between April 2005 and November 2009. We enrolled 167 patients with >50% stenosis or occlusion in culprit major vessels and who were administered oral antiplatelet agents within 48 hours of admission. Hemorrhagic complications were classified according to the bleeding severity index. We studied the association between the incidence and severity of hemorrhagic complications during hospitalization and the clinical characteristics, including antiplatelet therapy.
  
  
  RESULTS
  Fifty-nine and 108 patients were treated with only 1 antiplatelet agent and combination antiplatelet agents, respectively. Fourteen patients developed bleeds (3 major and 11 minor), and all of the major bleeds occurred in those given combination agents. The proportion of patients receiving combination agents was significantly higher in those with significant bleeds. Multivariate logistic regression analysis revealed that being older and receiving combination agents were independent predictors for significant bleeds during hospitalization.
  
  
  CONCLUSIONS
  Despite the retrospective nature of this study, our findings suggest that the incidence of hemorrhagic complications increases in patients with acute ischemic stroke treated with combination antiplatelet agents.
authors: Department of Stroke Neurology, Kohnan Hospital, Sendai, Miyagi, Japan. ritabash@kohnan-sendai.or.jp
authors: Ryo
authors: R
authors: Itabashi
authors: Etsuro
authors: E
authors: Mori
authors: Eisuke
authors: E
authors: Furui
authors: Shoichiro
authors: S
authors: Sato
authors: Yukako
authors: Y
authors: Yazawa
authors: Satoru
authors: S
authors: Fujiwara
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D002339:Carotid Arteries / Q000473:pathology*; D002533:Cerebral Angiography; D002536:Cerebral Arteries / Q000473:pathology*; D002560:Cerebrovascular Circulation / Q000502:physiology*; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced* / Q000150:complications; D006801:Humans; D015994:Incidence; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D012189:Retrospective Studies; D012307:Risk Factors; D020521:Stroke / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors